Overview research of uremic ulearance granule treating chronic renal failure

Zhongguo Zhongyao Zazhi

Volumn 38, Issue 21, 2013, Pages 3651-3655

  Meng, Xian Jie ^a   Wan, Yi Gang ^b   Wei, Qing Xue ^a   Chen, Hao Li ^a   Shi, Xi Miao ^a   Huang, Yan Ru ^a   Yao, Jian ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chronic renal failure; Pharmacological mechanism; Uremic clearance granul

Indexed keywords

CHINESE DRUG; TRANSFORMING GROWTH FACTOR BETA1;

CELL DAMAGE; CELL DIFFERENTIATION; CHINESE HERB; CHRONIC KIDNEY FAILURE; DRUG INHIBITION; GENE OVEREXPRESSION; IN VIVO STUDY; INSULIN RESISTANCE; MYOFIBROBLAST; OXIDATIVE STRESS; PODOCYTE; REVIEW; UREMIC CLEARANCE GRANULE;

EID: 84891954786     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20132110     Document Type: Review

References (42)

1. Abbord H, Henrich W L. Clinical practice. Stage IV chronic kidney disease[J]. N Engl J Med, 2010, 362(1): 56.
2. 2011, 36(9): 1122.
3. Tang D, He B, Zheng Z G, et al. Inhibitory effects of two major isoflavonoids in Radix Astragali on high glucose-induced mesangial cells proliferation and AGEs-induced endothelial cells apoptosis[J]. Planta Med, 2011, 77(7): 729.
4. Miao X H, Wang C G, Hu B Q, et al. TGF-beta1 immunohistochemistry and promoter methylation in chronic renal failure rats treated with uremic clearance granules[J]. Folia Histochem Cytobiol, 2010, 48(2): 284.
5. 2002, 13(5): 302.
6. 2005, 5(8): 1738.
7. 2011, 22(7): 657.
8. 2007, 28(9): 1093.
9. 2011, 36(19): 2603.
10. 2009, 18(9): 27.
11. 2013, 20(6): 45.
12. 2012, 13(8): 741.
13. 2009, 10(3): 238.
14. 2010, 26(24): 3735.
15. 2007, 28(9): 1187.
16. 2011, 39(3): 272.
17. 2012, 18(4): 505.
18. 2012, 18(27): 155.
19. Zhang D, Sun L, Xian W, et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity[J]. Lab Invest, 2010, 90(30): 436.
20. 2008, 26(8): 1656.
21. 2008, 25(6): 537.
22. Murakoshi M, Tanimoto M, Gohda T, et al. Mindin: a novel marker for podocyte injury in diabetic nephropathy[J]. Nephrol Dial Transplant, 2011, 26(7): 2153.
23. 2013, 14(2): 183.
24. 2008, 9(10): 875.
25. Fragiadaki M, Mason R M. Epithelial-mesenchymal transition in renal fibrosis-evidence for and against[J]. Int J Exp Pathol, 2011, 92(3): 143.
26. Liu S F, Chang S Y, Lee T C, et al. Dioscorea alata attenuates renal interstitial cellular fibrosis by regulating Smad-and epithelial-mesenchymal transition signaling pathways[J]. PLoS One, 2012, 7(11): e47482.
27. 2009, 26(6): 550.
28. Riella M C. Malnutrition in dialysis: malnourishment or uremic inflammatory response[J]. Kidney Int, 2000, 57(3): 1211.
29. 2010, 3(9): 70.
30. Popolo A, Autore G, Pinto A, et al. Oxidative stress in patients with cardiovascular disease and chronic renal failure[J]. Free Radic Res, 2013, 47(5): 346.
31. Kim H J, Vaziri N D. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure[J]. Am J Physiol Renal Physiol, 2010, 298(3): F662.
32. 2011, 12(5): 438.
33. Chen J, Muntner P, Hamm L L, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults[J]. J AM Soc Nephrol, 2003, 14(2): 469.
34. Chonchol M, Scragg R, Hydroxyvitamin D. Insulin resistance, and kidney function in the third national healtand nutrition examination survey[J]. Kidney Int, 2007, 71(1): 134.
35. 2010, 11(6): 537.
36. 2008: 1280.
37. 2009, 34(8): 939.
38. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis[J]. Am J Physiol Renal Physiol, 2002, 283(5): F861.
39. 2011, 36(20): 2893.
40. Xie Y M, Tian F. Regulations and guidelines should be strengthened urgently for re-evaluation on post-marketing medicines in China[J]. Chin J Integr Med, 2013, 19(7): 483.
41. 2011, 36(20): 2761.
42. Liao X, Robinson N. Methodological approaches to developing and establishing the body of evidence on post-marketing chinese medicine safety[J]. Chin J Integr Med, 2013, 19(7): 494.